Creation and assessment of a comprehensive and interpretable AI model for forecasting gout recurrence in hospitalized individuals: a real-world, ambispective multicenter cohort investigation in China - Summary - MDSpire

Creation and assessment of a comprehensive and interpretable AI model for forecasting gout recurrence in hospitalized individuals: a real-world, ambispective multicenter cohort investigation in China

  • By

  • Meng Li

  • Hui Zhang

  • Shixian Chen

  • Fei Zhong

  • Jiani Liu

  • Juan Wu

  • Ruifeng Lin

  • Ruichang Li

  • Yu Wu

  • Danning Xie

  • Kangyu Zhang

  • Bowen Zheng

  • Xiaoling Chen

  • Zhipeng Cheng

  • Yinxiu Jiang

  • Haixin Ye

  • Li Cai

  • Ruixia Xie

  • Dongsheng Li

  • Junqing Zhu

  • Juan Li

  • November 4, 2025

Share

Objective:

To identify predictive factors for gout recurrence (GoutRe) in hospitalized patients with comorbid gout and develop an interpretable AI model for predicting recurrence.

Approach:
    Key Findings:
    • Gout prevalence in China has significantly increased, reaching 3.2% in adults during 2015-2017, indicating a growing public health concern.
    • Recurrence rates of gout among hospitalized patients range from 14% to 43%, highlighting the need for effective management strategies.
    • Factors such as serum urate levels, diuretic use, and comorbidities are significantly associated with GoutRe, suggesting areas for targeted intervention.
    Interpretation:

    The study underscores the necessity for a comprehensive predictive model for GoutRe, which can assist clinicians in tailoring treatment plans and enhancing patient outcomes.

    Limitations:
    • Limited generalizability due to the study being conducted in specific tertiary hospitals, which may not represent the broader population.
    • Potential biases in retrospective data collection and patient selection could influence the reliability of the findings.
    Conclusion:

    The development of an AI model for predicting gout recurrence has the potential to significantly enhance clinical decision-making and reduce the burden of gout on patients and healthcare systems.

Original Source(s)

Related Content